Team

Meet the Experts Driving Innovation and Excellence

Our CRO Team

CRO team is comprised of dedicated professionals from diverse fields who are committed to advancing preclinical research and pharmaceutical services. With expertise spanning medical sciences, veterinary care, biostatistics, IT and web developers, Graphic designers and business development, we bring a wealth of knowledge and experience to every project.

Executive Management

Dr. Sanaullah Sajid (DVM,PhD)

CEO

Dr. Bilal (DVM,PhD)

Director Veterinary Labs

Clinical Operations

Dr. Ahmad Faraz (DVM, MPhil)

Study Director

Rabeea Laeeq (MPhil)

Project Manager

Maheen (PhD, Australia)

CRA

Amina Tayyab (Graduate)

CRA

Haseeb Ullah Sajid (Graduate)

CRA

Eman Ali (Graduate,USA)

CRA

Core Operations

Itrat Fatima Toor (MPhil)

HR Manager

M. Zain (PhD,Australia)

QA Manager

Dr. Samiullah Sajid (MBBS)

Medical writer

Bilal Murtaza (MPhil)

Biostatistician

M. Raza (LLB)

Legal Advisor

Information Tecnology

Seerat Fatima Toor (Graduate)

IT manager

Menahil Fatima Toor (Graduate)

Graphic designer

Our Global Perspective

With team members from Pakistan, UK, USA, China, and Australia, Prism CRO fosters a collaborative environment that embraces cultural diversity and global perspectives. This diverse team enables us to deliver innovative solutions tailored to meet the unique needs of our international clients.

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

This is the heading

Umar Hayat, Ph.D. is a founder of Trials 360 and has more than two decades of experience in pharmaceutical development, manufacturing and supply chain.  He held senior level positions with, Union Therapeutics,  Relypsa (acquired by Galenica for 1.52B US$), Anacor (acquired by Pfizer for 5.2B US$) and Transcept Pharmaceuticals (revers merger with Paratek). He played a pivotal role in the development and commercialization of Veltassa® (USA and EU), a treatment for hyperkalemia, Intermezzo® for MOTN insomnia, Kerydin® for onychomycosis, and Eucrisa® for atopic dermatitis.